kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2015-4-79-82kpccz-155Research ArticleАНАЛИТИЧЕСКИЕ ОБЗОРЫ ЛИТЕРАТУРЫANALYTICAL REVIEWS OF LITERATUREИНТЕРВЕНЦИОННАЯ КАРДИОЛОГИЯ – НОВОСТИ, СОБЫТИЯ И ТЕНДЕНЦИИ (по материалам on-line издания Cardiac Interventions Today)INTERVENTIONAL CARDIOLOGY – NEWS, EVENTS AND TRENDS («Cardiac Interventions Today»)МУРАШКОВСКИЙАндрей ЛеонидовичMURASHKOVSKYAndrey

650002, г. Кемерово, Сосновый бульвар, д. 6

6, Sosnoviy blvd., Kemerovo, 650002

muraal@kemcardio.ruГАНЮКОВВ. И.GANYUKOVV. I.

650002, г. Кемерово, Сосновый бульвар, д. 6

6, Sosnoviy blvd., Kemerovo, 650002

Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»РоссияFederal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular DiseasesRussian Federation201526112015047982Copyright © МУРАШКОВСКИЙ А.Л., ГАНЮКОВ В.И., 20152015МУРАШКОВСКИЙ А.Л., ГАНЮКОВ В.И.MURASHKOVSKY A., GANYUKOV V.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/155

В обзоре материалов, опубликованных в on-line издании «Cardiac Interventions Today» за 2015 год (Vol. 9), рассматриваются такие актуальные вопросы интервенционной кардиологии, как оказание помощи при остром инфаркте миокарда, осложненном кардиогенным шоком, и стратегия антитромбоцитарной терапии после чрескожного коронарного вмешательства.

In the review of publications in the «Cardiac Interventions Today» on-line edition (2015; Vol. 9) have been discussed such topical issues in interventional cardiology as treatment of acute myocardial infarction complicated by cardiogenic shock and the strategy of antiplatelet therapy after percutaneous coronary intervention.

инфаркт миокарда с подъемом сегмента STкардиогенный шоккоронарная реперфузияостаточная реактивность тромбоцитовmyocardial infarctionSTEMIcardiogenic shockantiplatelet medicationplatelet function testshigh on-treatment platelet reactivityReferencesO’Gara P. T., Kushner F. G., Ascheim D. D. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation / American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 2013; 61: e78–e140.O’Gara P. T., Kushner F. G., Ascheim D. D. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation / American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 2013; 61: e78–e140.Menees D. S., Peterson E. D., Wang Y. et al. Door-toballoon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 2013; 369: 901–909.Menees D. S., Peterson E. D., Wang Y. et al. Door-toballoon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 2013; 369: 901–909.Sleeper L. A., Ramanathan K., Picard M. H. et al. SHOCK Investigators. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J. Am. Coll. Cardiol. 2005; 46: 266–273.Sleeper L. A., Ramanathan K., Picard M. H. et al. SHOCK Investigators. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J. Am. Coll. Cardiol. 2005; 46: 266–273.Ezekowitz J. A., Kaul P., Bakal J. A. et al. Declining inhospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J. Am. Coll. Cardiol. 2009; 53: 13–20.Ezekowitz J. A., Kaul P., Bakal J. A. et al. Declining inhospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J. Am. Coll. Cardiol. 2009; 53: 13–20.Braunwald E., Kloner R. A. Myocardial reperfusion: a double-edged sword? J. Clin. Invest. 1985; 76: 1713–1719.Braunwald E., Kloner R. A. Myocardial reperfusion: a double-edged sword? J. Clin. Invest. 1985; 76: 1713–1719.Ong S. B., Samangouei P., Kalkhoran S. B., Hausenloy D. J. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J. Mol. Cell. Cardiol. 2015; 78C: 23–34.Ong S. B., Samangouei P., Kalkhoran S. B., Hausenloy D. J. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J. Mol. Cell. Cardiol. 2015; 78C: 23–34.Patel M. R., Smalling R. W., Thiele H. et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011; 306: 1329–1337.Patel M. R., Smalling R. W., Thiele H. et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011; 306: 1329–1337.O’Neill W. W., Schreiber T., Wohns D. H. et al. The current use of Impella 2,5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J. Interv. Cardiol. 2014; 27: 1–11.O’Neill W. W., Schreiber T., Wohns D. H. et al. The current use of Impella 2,5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J. Interv. Cardiol. 2014; 27: 1–11.Breet N. J., van Werkum J. W., Bouman H. J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303: 754–762.Breet N. J., van Werkum J. W., Bouman H. J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303: 754–762.Price M. J., Berger P. B., Teirstein P. S. et al. GRAVITAS Investigators. Standard – vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097–1105.Price M. J., Berger P. B., Teirstein P. S. et al. GRAVITAS Investigators. Standard – vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097–1105.Trenk D., Stone G. W., Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug–eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll .Cardiol. 2012; 59: 2159–2164.Trenk D., Stone G. W., Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug–eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll .Cardiol. 2012; 59: 2159–2164.Collet J. P., Cuisset T., Rangé G. et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 2012; 367: 2100–2109.Collet J. P., Cuisset T., Rangé G. et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 2012; 367: 2100–2109.Gurbel P. A., Erlinge D., Ohman E. M. et al. TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012; 308: 1785–1794.Gurbel P. A., Erlinge D., Ohman E. M. et al. TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012; 308: 1785–1794.

The authors declare that there are no conflicts of interest present.